Forecast

The analysts' average price target is €12.93 (+31.00%). The median is €12.93 (+31.00%).

Buy	20
Hold	21
Sell	1

News Go to news feed

FMC unveils turnaround plan focusing on de-leveraging, production restructuring and new active ingredients

FMC announced a turnaround plan at the Jefferies Global Industrials Conference that includes debt reduction (expected net debt by end-2026: $2.6–2.7bn, about $1bn from disposals/financings), restructuring of production sites (completion planned Q1 2027) and commercialization of new products such as fluindapyr, Isoflex and Dodhylex. Tessenderlo’s 20% stake with a three-year lock-up is intended to support the de-leveraging plan. Management sees 2027 as the start of recovery but expects Rynaxypyr stabilization and market tests in H2 2026 to be decisive; around 1,000 jobs are to be cut as part of the restructuring. FMC also emphasizes stronger partnerships to improve R&D efficiency and a repositioning of the core business with the aim of restoring growth above the market. » More on de.investing.com
FMC stock falls sharply after results and unchanged outlook

FMC’s stock plunged in pre-market trading after the company’s adjusted operating result in the second quarter surprised positively, but it confirmed its full-year outlook. Analysts at JPMorgan and UBS warned this could lead to lower estimates for the second half of the year. Bernstein also criticized weaker treatment numbers in the U.S.; the stock lost more than eight percent on Tradegate. » More on de.investing.com
FMC hits 52-week low at $10.55 amid high debt and asset sales

FMC shares fell to a 52-week low of $10.55, down 74.28% year‑over‑year. The company carries $4.66 billion in debt and a negative free cash flow (-$219.8 million). Tessenderlo is investing $400 million for a 20% stake to help reduce debt; FMC is also selling a parcel in Delaware for about $114 million and has filed an EPA registration dossier for the herbicide Rimisoxafen. BMO Capital reiterates a "Market Perform" rating, citing planned asset sales and the 2026 outlook. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, FMC Corp has already paid €0.21 in dividends. The last payout was in July.

Financials

In the last quarter, FMC Corp had revenue of €759.76m and net profit of -€163.5m

(EUR)	June 2026	YoY
Revenue	759.76m	14.75%
Gross profit	299.75m	13.26%
Net profit	-163.5m	388.92%
EBITDA	-71.76m	149.73%

Fundamentals

Metric	Value
Market capitalization	€1.3bn
Number of shares	125.23m
52-week high/low	€33.33 - €8.57
Dividend yield	7.12%
Dividends TTM	€0.70
Beta	0.42
P/E ratio	-0.55
PEG ratio	0.00
P/B ratio	0.92
P/S ratio	0.47

Company profile

FMC Corporation, ein Unternehmen der Agrarwissenschaften, bietet Produkte für den Pflanzenschutz, die Pflanzengesundheit und die professionelle Schädlingsbekämpfung und Rasenpflege an. Das Unternehmen entwickelt, vermarktet und verkauft chemische Pflanzenschutzmittel, darunter Insektizide, Herbizide und Fungizide, sowie biologische Produkte, Pflanzennahrung und Saatgutbehandlungsmittel, die in der Landwirtschaft zur Steigerung der Ernteerträge und -qualität durch die Bekämpfung einer Reihe von Insekten, Unkräutern und Krankheiten sowie in nicht-landwirtschaftlichen Märkten zur Schädlingsbekämpfung eingesetzt werden. Das Unternehmen vermarktet seine Produkte über seine eigene Vertriebsorganisation sowie über Allianzpartner, unabhängige Händler und Handelsvertreter. Das Unternehmen ist in Nordamerika, Lateinamerika, Europa, dem Nahen Osten, Afrika und Asien tätig. Die FMC Corporation wurde 1883 gegründet und hat ihren Hauptsitz in Philadelphia, Pennsylvania.